Welcome to our dedicated page for Nuo Therapeutics news (Ticker: AURX), a resource for investors and traders seeking the latest updates and insights on Nuo Therapeutics stock.
Nuo Therapeutics, Inc. (OTCQB: AURX) is a commercial-stage medical device and biomedical company focused on biodynamic therapies for chronic wound care. Its news flow centers on the development, commercialization, and clinical use of the Aurix System, an FDA-cleared autologous platelet-rich plasma (PRP) hematogel used for the management of chronic wounds and chronic diabetic wounds.
News about Nuo Therapeutics often highlights commercial agreements and distribution partnerships. The company has reported distribution arrangements with multiple entities experienced in blood-based biologics and wound care, including Pacific Medical, Inc. It has also announced that Aurix was added to the wound care formulary of Wound Care Advantage, and that PAM Health selected Aurix as the sole PRP wound care therapy across its network of long-term acute care hospitals, inpatient rehabilitation hospitals, and outpatient and wound care clinics.
Another key category of updates involves strategic collaborations and private label arrangements. Nuo Therapeutics has disclosed an exclusive private label distribution agreement with Smith+Nephew, under which Smith+Nephew will market and sell the CENTRIO Platelet-Rich Plasma System, based on the Aurix technology, to the United States wound care market while Nuo manufactures the product.
Investors and clinicians can also find news on regulatory and reimbursement milestones, such as the CMS national coverage decision for autologous PRP in chronic non-healing diabetic wounds, and on corporate developments including capital structure changes, recapitalization transactions, and responses to mini-tender offers. Updates on participation in industry events, such as selection to exhibit the Aurix System at the Vizient Innovative Technology Exchange, provide additional context on how the company engages with hospital and supply chain leaders.
This news page aggregates these announcements so readers can follow Nuo Therapeutics’ progress in expanding access to the Aurix System, evolving its distribution network, and navigating the reimbursement and regulatory landscape for advanced wound care therapies.
Nuo Therapeutics has secured an exclusive private label distribution agreement with Smith+Nephew for the U.S. wound care market. Under this partnership, Smith+Nephew will market Nuo's Aurix System under their own brand name, CENTRIO Platelet-Rich Plasma System.
Key aspects of the agreement include:
- Five-year initial term
- Upfront distribution fee for Nuo
- Minimum purchase commitments at agreed pricing
- Potential reimbursement coverage milestone payments
Nuo will maintain manufacturing responsibilities and continue selling their Aurix brand separately, subject to customer overlap conditions. This strategic partnership leverages Smith+Nephew's market-leading position in advanced wound care to expand the adoption of autologous PRP technology for treating chronic wounds.
Nuo Therapeutics (OTCQB: AURX) has entered a multi-year exclusive agreement with PAM Health to provide its Aurix System as the sole platelet-rich plasma (PRP) wound care therapy across PAM Health's network. The partnership spans all PAM Health's facilities including long-term acute care hospitals, rehabilitation centers, and wound care clinics across 23 states.
The Aurix System, the first FDA-cleared autologous PRP therapy for chronic wounds, utilizes a one-minute spin process to create a biologically active gel from the patient's platelets and plasma. Clinical studies, including collaborations with Medicare & Medicaid Services, have shown superior healing rates compared to other advanced wound modalities.
This partnership addresses a significant healthcare challenge, as chronic wounds affect 2% of the US population and over 8 million Medicare beneficiaries, with annual Medicare spending ranging from $28.1 to $96.8 billion. The condition leads to over 100,000 diabetic amputations annually, with a five-year post-amputation mortality rate of nearly 62%.
Summary not available.
Summary not available.
Nuo Therapeutics, Inc. (OTCQB: AURX) has announced a strategic equity agreement with Pacific Medical, Inc., which includes an initial $500,000 purchase of common stock. This partnership aims to enhance the distribution and sales of the Aurix product, a biodynamic therapy for chronic wounds. With approximately $4.5 million raised this year, Nuo is positioned to further its commercial goals. The North American advanced wound care market is projected to reach $3.6 billion in 2022, driven by an increasing prevalence of chronic wounds. Nuo is also exploring potential uplisting to a national exchange.
Nuo Therapeutics announced awareness of an unsolicited mini-tender offer from Alternative Liquidity Index, LP to purchase 1,820,000 shares, roughly 4.9% of its outstanding shares, at $0.01 each. The company emphasizes it is not associated with this offer and warns investors about the risks of mini-tender offers, which lack comprehensive SEC disclosure protections. The offered price is significantly lower than the recent warrant exercise price of $0.20 per share. Nuo intends to file overdue financial reports to regain compliance with SEC obligations.
Nuo Therapeutics, Inc. (OTC Pink: AURX) announced on April 20, 2021, the publication of a final decision memo from the Centers for Medicare & Medicaid Services (CMS) regarding coverage for autologous platelet-rich plasma (PRP) therapy for chronic non-healing diabetic foot ulcers (DFUs). Medicare will cover PRP treatments for up to 20 weeks, with specific FDA clearance requirements for devices. CEO David Jorden highlighted the significance of this decision and the company's efforts to improve clinical data since its previous non-coverage ruling in 2008. The company aims to ensure Aurix is accessible to patients.
Nuo Therapeutics, Inc. (OTC Pink: AURX) announced the closing of a recapitalization and exchange agreement that simplifies its capital structure. The agreement involved an exchange of Series A Preferred Stock for 2.7 million common shares and conversion of approximately $330,000 of secured notes into 838,487 shares. The transaction leaves the company with no debt and around 29.2 million shares outstanding. The CEO noted potential improvements pending a decision from CMS regarding national coverage for the Aurix product, crucial for the company's future viability.
FAQ
What is the current stock price of Nuo Therapeutics (AURX)?
What is the market cap of Nuo Therapeutics (AURX)?
